Biocompatibles sales heading higher

16 July 2001

UK firm Biocompatibles International says that sales of PC(phosphorylcholine) technology products and its cardiovascular and eye-care divisions in the first two months of 2001, were well ahead of the like, 2000 period, although Hydron eye-care products remained static.

In the cardiovascular division, first-half 2001 turnover of the firm's BiodivYsio line of PC technology stent products were around 43% higher, with strong sales growth seen in the UK, Germany, Latin America and Asia. In the drug delivery division, recruitment was completed in a trial for the dexamethasone-loaded stent (STRIDE), and the trial of a stent delivering British Biotech's batimastat (BRILLIANT) is expected to start shortly.

First-half sales of the eye-care division were around 17% ahead of 2000 on a like-for-like basis, with turnover of the Proclear line of PC technology products up 38%. The strongest areas of growth were the countries where the acquisition of Hydron provided new direct sales forces, notably in the Netherlands, Italy, Spain, France, Australia and South Africa.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight